Biomarkers of nivolumab benefit in resectable non-small cell lung cancer

Exploratory biomarker analyses were performed in 190 patients (nivolumab, 98 out of 229 (43%); placebo, 92 out of 232 (40%)) with evaluable paired tumour samples from screening and blood samples from… [+18319 chars]